Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
DUBLIN, Ireland, Dec. 15, 2016 -- HiberGene Diagnostics, a company focussed on applying molecular technology to the infectious disease segment of the diagnostics market, has announced that it has CE marked its HG C. difficile test.
HG C. difficile enables the rapid and accurate detection of the bacterium, Clostridium difficile (C. difficile), from stool samples in under 60 minutes. C. difficile is the major cause of hospital-acquired diarrhoea which can be fatal, particularly in elderly and immuno-compromised patients. Furthermore, the highly infectious nature of the bacterium, coupled with its resistance to current standard cleaning methods, means it can spread quickly leading to serious outbreaks in healthcare facilities.
The launch of HG C. difficile is the third in HiberGene’s expanding portfolio of tests which includes Meningococcus and Group B Streptococcus. In addition, the utility of the Meningococcus and Group B Streptococcus was recently expanded with the inclusion of a direct swab capability.
Commonly-used test methods for C. difficile include time-consuming cell culture techniques and frequently insensitive enzyme assays. HiberGene’s highly sensitive and specific C. difficile test takes approximately an hour and can be performed outside the laboratory setting.
Brendan Farrell, CEO of HiberGene, said: “The launch of the HG C. difficile test will help in tackling the spread of C. difficile in clinical environments. The spread of C. difficile can cause significant ill health, despite its relative ease to tackle. However, the inability to provide a rapid, on the spot, diagnosis can often result in a delay in effective treatment being administered. By using the HG C. difficile test, health professionals can now quickly and easily diagnose the presence of the bacterium and provide an effective treatment.”
Notes to Editors:
About HiberGene
HiberGene is a diagnostics company focussed on applying molecular technology to the infectious disease segment of the diagnostic market. Utilising the LAMP platform, HiberGene has developed rapid and highly sensitive diagnostic tests for Meningococcus, Group B Streptococcus and C. difficile which can be used in almost any clinical or laboratory setting. HiberGene intends to continue to expand its test menu for the detection of human infectious diseases.
www.hibergene.com
For more information, please contact: Tony Stephenson Exitus Communications Tel: +44 (0)7899 796655 Email: [email protected] Brendan Farrell Chairman & CEO HiberGene Diagnostics Limited Email: [email protected]
